PTC Therapeutics Inc (PTCT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.30B
Last updated: Nov 17, 2026 at 11:06 AM ET
PTC Therapeutics Inc (PTCT) Stock Forecast
Analysts expect PTC Therapeutics (PTCT) to earn $0.94 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.32B. Of 15 analysts, 13 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 1.87, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 87% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 26.7% |
| Buy | 9 | 60.0% |
| Hold | 2 | 13.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 239.4% and revenue estimates rise 8.3%.
- Fiscal year ending Dec 31, 2026
- $0.94
- EPS consensus, revenue $1.32B
- Fiscal year ending Dec 31, 2027
- $3.19
- EPS consensus, revenue $1.43B
- Next report
- Feb 17, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.94 | $0.73 to $1.14 | 2 | $1.32B | $1.29B to $1.34B | 14 |
| Dec 31, 2027 | $3.19 | $3.04 to $3.34 | 2 | $1.43B | $1.18B to $1.67B | 14 |
Quarterly Estimates
The EPS consensus rises from $0.40 for the quarter ending Dec 31, 2026 to $0.52 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.40 | $0.09 to $0.94 | 17 | $336.93M | $297.21M to $365.40M | 15 |
| Mar 31, 2027 | $0.52 | -$0.01 to $1.38 | 7 | $313.41M | $291.64M to $341.40M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 41.3% from $1.60.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.94 | $1.52 | $1.71 | $1.60 | $1.60 | -41.4% |
| Fiscal year ending Dec 31, 2027 | $3.19 | $2.37 | $2.68 | $2.50 | $2.50 | +27.6% |
| Quarter ending Mar 31, 2027 | $0.52 | $0.37 | $0.14 | $0.19 | $0.21 | +145.5% |
Frequently Asked Questions About PTCT
What is the PTCT stock forecast?
Consensus analyst estimates put PTC Therapeutics's EPS at $0.94 for the fiscal year ending Dec 31, 2026, on revenue of $1.32B. The consensus rating from 15 analysts is Buy.
How do analysts rate PTCT stock?
Of 15 analysts covering PTC Therapeutics, 4 rate it Strong Buy, 9 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PTCT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.94, with estimates from $0.73 to $1.14 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.19, with estimates from $3.04 to $3.34 from 2 analysts.
What revenue do analysts expect from PTC Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.32B, with estimates from $1.29B to $1.34B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.43B, with estimates from $1.18B to $1.67B.
How many analysts cover PTCT?
15 analysts rate PTC Therapeutics stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PTCT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors